The sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction in a rat bypass model
Biochemical Pharmacology · 2026-02 · 244 · 117601
DOI: 10.1016/j.bcp.2025.117601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-02. Verfasst von Ming Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Endothelium, Vascular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Heidelberg, China Scholarship Council.
Abstract (Originalsprache)
Ischemia/reperfusion (IR) injury during coronary artery bypass grafting surgery has detrimental impacts on endothelial integrity and function. Studies have suggested that canagliflozin (CANA) mitigates the risk of cardiovascular events, independently of diabetes. We hypothesized that the supplementation and/or administration of CANA protects vascular grafts in a bypass model in non-diabetic Lewis rats. The aortic arches of control rats (n = 9) were harvested, aortic rings were prepared, then mounted in organ baths. In the IR and IR + CANAsuppl groups (n = 8/group), aortic arches were preserved in either saline or CANA-supplemented saline (5 µM) for 1 h at 4 °C before transplantation. In the IR + CANAinject and IR + CANAsuppl+inject groups (n = 9/group), aortic arches were preserved in cold saline or CANA for 1 h and recipients received CANA (10 µg/kg, intravenous) 5 min prior to reperfusion. After 1 h of in vivo blood reperfusion, ex vivo vascular function was assessed and immunohistochemistry was performed. The decreased maximum relaxation (Rmax) to acetylcholine in the IR group compared to controls (20 ± 3 % vs 83 ± 2 %, p < 0.05) was improved in both the IR + CANAinject (36 ± 2 % vs. 20 ± 3 %, p < 0.05) and IR + CANAsuppl+inject (45 ± 3 % vs. 20 ± 3 %, p < 0.05) groups. Additionally, the IR + CANAsuppl+inject rings exhibited a further increased Rmax to acetylcholine compared to both the IR + CANAsuppl (45 ± 3 % vs. 31 ± 2 %, p < 0.05) and IR + CANAinject (45 ± 3 % vs. 36 ± 2 %, p < 0.05) groups. Increased DNA strand breaks in the IR group compared to controls were decreased in all CANA groups. The reduced immunoreactivity of CD-31 was ameliorated in the IR + CANAinject and IR + CANAsuppl+inject groups. CANA alleviates endothelial dysfunction induced by IR injury in a rodent model of revascularization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.
- Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany; Department of Vascular Surgery, General Surgery Clinical Center, Shanghai General Hospital, Shanghai Jiao Tong University School…
- Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany; Heart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.
- Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany; Department of Cardiac Surgery, University Hospital Halle (Saale), 06120 Halle, Germany.
- Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany; Department of Cardiac Surgery, University Hospital Halle (Saale), 06120 Halle, Germany. Electronic address: korkmaz@uni-heidelber…
Förderung
- Universitätsklinikum Heidelberg
- China Scholarship Council
Zitieren
APA
Ma, M., Lian, S., Kraft, P., Mayer, T., Sayour, A. A., Karck, M., Szabó, G., & Korkmaz-Icöz, S. (2026). The sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction in a rat bypass model. Biochemical Pharmacology, 244, 117601. https://doi.org/10.1016/j.bcp.2025.117601
Vancouver
Ma M, Lian S, Kraft P, Mayer T, Sayour AA, Karck M, et al. The sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction in a rat bypass model. Biochemical Pharmacology. 2026;244:117601. doi:10.1016/j.bcp.2025.117601
BibTeX
@article{Ma2026,
author = {Ma, Ming and Lian, Shuo and Kraft, Patricia and Mayer, Tobias and Sayour, Alex Ali and Karck, Matthias and Szabó, Gábor and Korkmaz-Icöz, Sevil},
title = {The sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction in a rat bypass model},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {244},
pages = {117601},
doi = {10.1016/j.bcp.2025.117601}
}
EUVIMED